A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: Blood-First Assay Screening Trial
This is a phase 2/3, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in combination in participants with unresectable, advanced or metastatic NSCLC determined to harbor oncogenic somatic mutations or positive by tumor mutational burden (TMB) assay as identified by two blood-based next-generation sequencing (NGS) circulating tumor DNA (ctDNA) assays.
Advanced or Metastatic Non-Small Cell Lung Cancer
Female or male ≥18 years of age
Confirmed diagnosis of unresectable Stage IIIb (advanced) or Stage IV (metastatic) NSCLC
18 - 120
Healthy Volunteers Needed
Duration of Participation
Your length in time in the study, including the screening, treatment, and follow-up periods, will be about 4-6 years.
Knight Cancer Institute Clinical Trials
F. Hoffmann-La Roche Ltd